In this video, Andre Goy, MD, gives insight into the center’s personalized experience discussing his approach to a patient’s treatment journey. Watch now. Dr. Goy physician in chief, Hackensack Meridian Health Oncology Care Transformation Services, chairman, chief physician officer, chief, Lymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center.
Transcript
My name is Andre Goy. I'm the chair at John Theurer Cancer Center and Division Chief of the Lymphoma program as well as a Physician in Chief Oncology for Hackensack Meridian Health. When I was in medical school, I was very interested in lab research and transitional aspect of things and innovation. And I wanted to specialty that will be a dynamic specialty that was when I first see a patient I'm very curious about and I want to understand who they are and I think it helps me a lot down the road when I need to take them somewhere. Sometimes it's easy to the treatment, and it's very helpful. You also need to understand the dynamics of the ecosystem, the patient what's happening in their family and their surroundings, because it also helps you take into account when you make treatment decisions. I think that if you've done this for so long to develop almost like a sixth sense of where you have to do, but I always say think outside the box. You need to be really confident in what you do to be able to go out of your comfort zone, but that's the beauty of it. That's what makes medicine hard and that's what wakes me up every morning because I keep going. That's why whenever he came the deputy chair and then the chair, people thought it was gonna stop. Same patient. I'm not gonna stop seeing patients actually think that every administrator should see patient and there's nothing better than saving someone's life.
Dr. Lacouture on managing dermatological adverse events with apalutamide in prostate cancer
February 7th 2022To investigate the severity and prevalence of dermatologic adverse events associated with apalutamide, Mario E. Lacouture, MD, and investigators conducted a study that will help to manage and counsel patients with prostate cancer in the future, especially with the expanded approval of apalutamide in this space.
How appropriate use criteria for PSMA-PET imaging optimize patient care
February 2nd 2022In a recent interview, Hossein Jadvar, MD, PhD, discussed what the appropriate use criteria consist of for prostate-specific membrane antigen (PSMA)-PET imaging, and why these criteria are vital in ensuring the individualized care of patients.
Dr. Padmanabhan discusses impact of COVID-19
June 11th 2020Urology Times® Editorial Council Member Priya Padmanabhan, MD, MPH, professor of urology at Oakland University William Beaumont School of Medicine, Royal Oak, Michigan, discusses how she has been affected by the coronavirus disease 2019 (COVID-19) pandemic.